Advertisement

Analysis of Circulating HMGB1 in Human Serum

  • Weiqiang Chen
  • Guoqiang Bao
  • Lin Zhao
  • Haichao WangEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2108)

Abstract

As a ubiquitous nuclear protein, high-mobility group box 1 (HMGB1) is constitutively expressed and can be actively secreted by macrophages/monocytes, as well as passively released from damaged cells following pathological injuries. Studies indicate that HMGB1 functions as a mediator of infection- and injury-elicited inflammatory diseases. Although intracellular HMGB1 functions as a regulator of tumorigenesis, epigenetic anticancer agents or therapeutic γ-ray irradiation could also cause active secretion or passive release of HMGB1, enabling serum HMGB1 to serve as a biomarker for the diagnosis and therapy of various cancers. Here we describe a semiquantitative immune blotting method to measure HMGB1 in human serum, in comparison with a commercially available HMGB1 enzyme-linked immunosorbent assay (ELISA) technique.

Key words

HMGB1 Western blotting ELISA Serum Antibody 

Notes

Acknowledgments

Work in the authors’ laboratory was supported by grants from the National Institutes of Health (R01GM063075 and R01AT005076).

References

  1. 1.
    Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Bonaldi T, Talamo F, Scaffidi P et al (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22:5551–5560PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342PubMedCrossRefGoogle Scholar
  4. 4.
    Ivanov S, Dragoi AM, Wang X et al (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110:1970–1981PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Rendon-Mitchell B, Ochani M, Li J et al (2003) IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 170:3890–3897PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Tang D, Shi Y, Kang R et al (2007) Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 81:741–747PubMedCrossRefGoogle Scholar
  7. 7.
    Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191–195PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Wang H, Ward MF, Fan XG et al (2006) Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 19:3–9PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Zhu S, Li W, Ward MF et al (2010) High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets 9:60–72PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Wang H, Ward MF, Sama AE (2009) Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 32:348–357PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Wang H, Yang H, Tracey KJ (2004) Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255:320–331PubMedCrossRefGoogle Scholar
  12. 12.
    Wang H, Li W, Goldstein R, Tracey KJ, Sama AE (2007) HMGB1 as a potential therapeutic target. Novartis Found Symp 280:73–85PubMedGoogle Scholar
  13. 13.
    Wang H, Zhu S, Zhou R et al (2008) Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med 10:e32PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Kang R, Xie Y, Zhang Q et al (2017) Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res 27:916–932PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Jiao Y, Wang HC, Fan SJ (2007) Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 28:1957–1967PubMedCrossRefGoogle Scholar
  16. 16.
    Liu P, Zhao L, Loos F et al (2018) Epigenetic anticancer agents cause HMGB1 release in vivo. Oncoimmunology 7:e1431090PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Wang L, He L, Bao G et al (2016) Ionizing radiation induces HMGB1 cytoplasmic translocation and extracellular release. Guo Ji Fang She Yi Xue He Yi Xue Za Zhi 40:91–99PubMedPubMedCentralGoogle Scholar
  18. 18.
    Bald T, Quast T, Landsberg J et al (2014) Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507:109–113PubMedCrossRefGoogle Scholar
  19. 19.
    Kargi A, Demirpence O, Gunduz S et al (2016) Serum levels of HMGB1 have a diagnostic role in metastatic renal cell cancer. Cancer Biomark 17:17–20PubMedCrossRefGoogle Scholar
  20. 20.
    Napolitano A, Antoine DJ, Pellegrini L et al (2016) HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res 22:3087–3096PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Urbonaviciute V, Furnrohr BG, Weber C et al (2007) Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 81:67–74PubMedCrossRefGoogle Scholar
  22. 22.
    Sha Y, Zmijewski J, Xu Z, Abraham E (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 180:2531–2537PubMedCrossRefGoogle Scholar
  23. 23.
    Lehner J, Wittwer C, Fersching D et al (2012) Methodological and preanalytical evaluation of an HMGB1 immunoassay. Anticancer Res 32:2059–2062PubMedGoogle Scholar
  24. 24.
    He RL, Zhou J, Hanson CZ et al (2009) Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 113:429–437PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Yasuda T, Ueda T, Takeyama Y et al (2006) Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 33:359–363PubMedCrossRefGoogle Scholar
  26. 26.
    Gaini S, Pedersen SS, Koldkjaer OG et al (2007) High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care 11:R32PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Okazaki K, Kondo M, Kato M et al (2008) Elevation of high-mobility group box 1 concentration in asphyxiated neonates. Neonatology 94:105–109PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Karlsson S, Pettila V, Tenhunen J et al (2008) HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 34(6):1046–1053PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Rowe SM, Jackson PL, Liu G et al (2008) Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 178:822–831PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Yoshizaki A, Komura K, Iwata Y et al (2009) Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 29:180–189PubMedCrossRefGoogle Scholar
  31. 31.
    Chung HW, Lee SG, Kim H et al (2009) Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 7:38.  https://doi.org/10.1186/1479-5876-7-38CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Dupire G, Nicaise C, Gangji V, Soyfoo MS (2012) Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjogren’s syndrome. Scand J Rheumatol 41:120–123PubMedCrossRefGoogle Scholar
  33. 33.
    Lee H, Song M, Shin N et al (2012) Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 7:e34318PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ (2001) HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164:1768–1773PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Angus DC, Yang L, Kong L et al (2007) Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 35:1061–1067PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Kazama H, Ricci JE, Herndon JM et al (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29:21–32PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Park JS, Arcaroli J, Yum HK et al (2003) Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284:C870–C879PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Li W, Li J, Sama AE, Wang H (2013) Carbenoxolone blocks endotoxin-induced PKR activation and HMGB1 release. Mol Med 19:203–211PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Li W, Li J, Ashok M et al (2007) A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 178:3856–3864PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Wang H, Liao H, Ochani M et al (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10:1216–1221PubMedCrossRefGoogle Scholar
  41. 41.
    Li W, Zhu S, Li J et al (2011) A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 6:e16945PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Li W, Ashok M, Li J et al (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One 2:e1153PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Yang H, Ochani M, Li J et al (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101:296–301PubMedCrossRefGoogle Scholar
  44. 44.
    Manganelli V, Signore M, Pacini I et al (2010) Increased HMGB1 expression and release by mononuclear cells following surgical/anesthesia trauma. Crit Care 14:R197PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Zhou Y, Xiong KL, Lin S et al (2010) Elevation of high-mobility group protein box-1 in serum correlates with severity of acute intracerebral hemorrhage. Mediat Inflamm 2010:142458.  https://doi.org/10.1155/2010/142458. Epub 2010 Sep 29CrossRefGoogle Scholar
  46. 46.
    Bruchfeld A, Wendt M, Bratt J et al (2011) High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 17:29–35PubMedCrossRefGoogle Scholar
  47. 47.
    Shang GH, Jia CQ, Tian H et al (2009) Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 103:1949–1953PubMedCrossRefGoogle Scholar
  48. 48.
    Goldstein RS, Gallowitsch-Puerta M, Yang L et al (2006) Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25:571–574PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Weiqiang Chen
    • 1
  • Guoqiang Bao
    • 1
  • Lin Zhao
    • 1
  • Haichao Wang
    • 1
    • 2
    • 3
    Email author
  1. 1.Laboratory of Emergency MedicineThe Feinstein Institute for Medical ResearchManhassetUSA
  2. 2.Donald and Barbara Zucker School of Medicine at Hofstra/NorthwellHempsteadUSA
  3. 3.The Feinstein Institute for Medical ResearchNorthwell Health SystemManhassetUSA

Personalised recommendations